Researchers now succeeded in making leukemia-specific immune cells less sensitive to the influence of tumor cells, thereby significantly increasing their effectiveness.
A new approach to fight glioblastoma: Swiss researchers have now developed an immunotherapy that not only attacks the brain tumor—it also turns its microenvironment against it.
Scientists at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have developed CAR-T cells capable of targeting malignant gliomas while preserving healthy tissue.
Chemotherapy, radiotherapy or surgery – these are the three common forms of cancer therapy. Now, lymphoma specialists in Essen are investigating the possibility of a different approach.
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy treatment that re-engineers a patient’s own T-cells to help them attack malignant tumour cells. It has been very effective in the treatment of blood cancers, including certain types of leukaemia and lymphoma. However, two serious side effects are common as a result of the treatment: cytokine release syndrome (CRS) and immune…
Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently…
The COVID-19 pandemic has impacted virtually every aspect of cancer care and research– from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research.
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body. Chimeric Antigen Receptor (CAR)-T cell therapy, for instance, is a…
In haematology and medical oncology, there is always something new. However, the increasing stratification of cancer therapies presents an enormous challenge for clinical research. Tumour cells – those altered genetically by mutation and thus ought to be recognised by the immune system and destroyed – manage to apply diverse molecular tricks to avoid attack by the immune system. Thus, they…
A team of scientists at the Keck School of Medicine of USC is looking to some deep sea dwellers to create a better way to develop cancer-fighting therapies. Harnessing the power of the enzymes that give these marine animals the ability to glow, the team created a test that makes it easy for researchers to see whether a therapy is having its intended effect — killing cancer cells. The results of…
Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the potential to create long-term immunity from the virus…
Every cancer is different and every patient is different. This insight gained in personalised medicine prompted oncology researchers to focus more on the individual patient’s immune system. It is particularly the immune system’s ability to destroy cancer cells that raised hope.
apceth announced a broad partnership with the Center for Molecular Medicine Cologne (CMMC), University of Cologne, to combine technologies and expertise, on the development of immunotherapies for solid tumors and haematological malignancies. The collaboration will start immediately and is based on combinations of Chimeric Antigen Receptor (CAR) T cells, developed at the laboratory of Prof Hinrich…